Slone Partners Recruits CEO for Magnetic Insight

April 17, 2024 – Life sciences-focused search firm Slone Partners has recruited Chris A. Raanes as the new CEO of Magnetic Insight, a global provider of magnetic particle imaging (MPI). “Chris Raanes is a highly accomplished and respected leader in the quickly evolving medical device field with the vision and management acumen necessary to engage all stakeholders in a growing, successful enterprise,” said Sona Stroud, senior vice president, executive search and partner at Slone Partners. “He will be a tremendously valuable addition to the excellent leadership team at Magnetic Insight.”

“We are delighted to welcome Chris to the Magnetic Insight team at a time when we are primed to make significant advancements in MPI technology, opening doors to a wide range of applications for a variety of medical conditions,” said company co-founder Patrick Goodwill. “Chris will drive our transition from the preclinical to the clinical space, transforming what is possible in the medical imaging field.”

Mr. Raanes has more than 20 years of experience in the medical device sector, having led companies through various stages of growth and commercialization. Previously, he served as president and CEO at Spire Health, where he supported the commercialization of a wearable sensor for respiratory patients. Before this, Mr. Raanes was president and CEO of ViewRay, where he brought the company public on the NASDAQ and led the commercial introduction of the MRIdian, an MRI-guided radiation therapy system. He also held executive positions at Accuray Incorporated and Perkin Elmer Optoelectronics.

“I’m honored to join the Magnetic Insight team, especially at such a pivotal time for groundbreaking research and advancements in the MPI space,” said Mr. Raanes. “This technology has the potential to reimagine medical imaging, expanding the field’s capabilities and providing an alternative to using radiation in many critical applications.”

Related: Slone Partners Recruits CFO for Clear Labs

Magnetic Insight introduces magnetic particle imaging, a groundbreaking imaging technology addressing today’s clinical and translational research challenges. Established in 2014, the company is headquartered in Alameda, CA.

Nationally Recognized

Slone Partners is a nationally recognized senior-level recruitment provider that specializes in delivering executive, management, and leadership talent for the diagnostic, biopharmaceutical, healthcare information technology, and laboratory testing industries. The firm has offices in Boston, New York, Washington, D.C., and San Francisco. Recently, Slone Partners was included among Hunt Scanlon Media’s “Top 50 Healthcare & Life Sciences Search Firms.”

Slone Partners Recruits Co-CEO for EarlyDiagnostics
Slone Partners has placed Gregory C. Critchfield as co-CEO of EarlyDiagnostics (EarlyDx), a leading company in liquid biopsy methylome detection of early cancer. “Greg Critchfield is a highly accomplished and respected life sciences executive with the deep knowledge and experience needed to drive a growth-focused company forward,” said Leslie Loveless, managing partner and CEO at Slone Partners. “He will be a tremendously valuable addition to the EarlyDiagnostics leadership team as the company prepares to launch its new commercial products.”

In 2000, Adam Slone founded Slone Partners and acted as CEO from 2000 to 2016. He remains chairman today. His industry knowledge and extensive contacts have enabled Slone Partners to place thousands of executives and industry professionals. Today, Mr. Slone remains engaged with Slone Partners, with a specific focus in strategy, finance, M&A advisement, and business development in Boston and California.

Leslie Loveless has nearly 20 years of healthcare industry and executive search experience to Slone Partners. She joined the firm in 2007, became COO in 2014 and CEO in 2016. At Slone Partners, Ms. Loveless acts as the leader of the organization as well as the head of the executive search team. Her involvement with clients and candidates enables her to understand the key motivations of each. As CEO, Ms. Loveless’ focus extends to cultivating new business partnerships and expanding relationships with existing clients. Through her leadership, life sciences and biotechnology have emerged as the primary client base for Slone Partners.

With more than 20 years of experience in healthcare and life sciences, Ms. Stroud has extensive market knowledge and a track record of key executive and leadership placements across multiple verticals and a wide array of companies. Before joining Slone Partners in 2011, she spent nearly a decade with Pfizer.

Related: Slone Partners Recruits Chief Business Officer for 1910 Genetics

Contributed by Scott A. Scanlon, Editor-in-Chief; Dale M. Zupsansky, Executive Editor; Lily Fauver, Senior Editor – Hunt Scanlon Media

Share This Article


Notify of
Inline Feedbacks
View all comments